InSightec to Exhibit ExAblate(R) 2000 Technology at Two Upcoming OB/GYN Conferences

    HAIFA, Israel, October 19 /PRNewswire/ -- To ensure that more women have
 access to and learn about non-invasive treatment options for symptomatic
 uterine fibroids, InSightec has launched an educational program on its
 ExAblate(R) 2000 procedure for obstetrician/gynecologists (OB/GYNs), the
 company said today. The ExAblate(R) 2000 will be highlighted at two OB/GYN
 medical conferences this fall: the meeting of the 61st Annual meeting of the
 American Society for Reproductive Medicine (ASRM) held conjointly with the
 Canadian Fertility and Andrology Society, October 15-19 in Montreal; as well
 as the Global Congress of Minimally Invasive Gynecology at the American
 Association of Gynecologic Laparoscopists (AAGL) 34th Annual Meeting in
 Chicago, November 9 -12.
     The ExAblate 2000 combines magnetic resonance imaging (MRI) with
 highly-focused ultrasound to destroy tumors non-invasively in the body.
 ExAblate 2000 is the first U.S. Food and Drug Administration-approved system
 to use the breakthrough MR-guided focused ultrasound technology that combines
 MRI to visualize the uterus and high intensity focused ultrasound to
 thermally ablate or destroy harmful tissue.
     To date, approximately 1,200 women have been treated with ExAblate 2000
 for uterine fibroids, a benign condition that affects approximately 25
 percent of women. Clinical trials are underway for bone, liver, and breast
 tumors.
     At ASRM on Saturday, Oct. 15, Elizabeth A. Stewart, M.D., Clinical
 Director of the Center for Uterine Fibroids at Brigham and Women's Hospital
 and Associate Professor of Obstetrics, Gynecology and Reproductive Biology at
 Harvard Medical School, discussed research on this modality of treatment for
 uterine fibroids as a part of her presentation of Innovative Therapies in the
 session entitled "Modern Approaches to Uterine Fibroids."
     "As the body of clinical data continues to grow in support of minimally-
 and non-invasive techniques for uterine fibroids, more OB/GYNs are
 recognizing the value this new MR-guided focused ultrasound technology holds
 for treating women with symptomatic uterine fibroids," said Dr. Stewart.
 "Women who may not have previously undergone uterine fibroid therapy because
 of the hospital stays, risks and side effects involved with traditional
 treatments now have the option to threat their condition in the outpatient
 setting without surgery."
     At ASRM, InSightec exhibited the ExAblate 2000 in the GE Healthcare
 booths (#113 and #117). In August, InSightec signed a global sales and
 marketing agreement with GE Healthcare for the sales and marketing of its
 ExAblate(R) 2000. The ExAblate 2000 works exclusively with the Signa MR
 systems made by GE Healthcare.
     At AAGL, InSightec will exhibit the ExAblate 2000 at booth #718. In
 addition, the ExAblate 2000 will be discussed during a postgraduate course on
 excisional and non-excisional management of uterine leiomyomas during the
 conference on Wednesday, Nov. 9th.
     About InSightec
     InSightec Image Guided Treatment Ltd. is a privately held company owned
 by Elbit Medical Imaging (EMI), General Electric, private investors and
 employees. It was founded in 1999 to develop the breakthrough MR guided
 Focused Ultrasound technology and transform it into the next generation
 operating room. Headquartered near Haifa, Israel, the company has over 100
 employees and has invested more than $80 million in research, development,
 and clinical investigations. Its U.S. headquarters are located in Dallas,
 Texas. For more information, please go to: http://www.insightec.com/
 
     Contact Information
 
     InSightec
     www.insightec.com
     Tel: +972-4-813-1313
     Email: info@insightec.com
 
     For media inquiries, contact:
 
     Fern Lazar
     Lazar Partners, Ltd.
     Tel: +1-212-867-1762
     Email: flazar@lazarpartners.com
 
     For more information about uterine fibroids, please visit
 http://www.uterine-fibroids.org
 
 

SOURCE  InSightec Ltd.